OncoTargets and Therapy
Volume 14, 2021 - Issue
Open access
91
Views
4
CrossRef citations to date
0
Altmetric
Original Research
Combination Therapy with iRGD-antiCD3 and PD-1 Blockade Enhances Antitumor Potency of Cord Blood-Derived T Cells
Mei Zhu1 The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, Jiangsu, 210008, People’s Republic of China;2 The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu, 210008, People’s Republic of China;3 Department of Oncology, Xuzhou Cancer Hospital, Xuzhou, Jiangsu, 221005, People’s Republic of China
, Hongmei Wang1 The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, Jiangsu, 210008, People’s Republic of China;2 The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu, 210008, People’s Republic of China
, Shujuan Zhou4 The Department of Radiation Oncology, Fudan University Shanghai Cancer Centre, Shanghai, 200032, People’s Republic of China
, Jia Wei2 The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu, 210008, People’s Republic of China
, Naiqing Ding2 The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu, 210008, People’s Republic of China
, Jie Shao2 The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu, 210008, People’s Republic of China
, Lixia Yu2 The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu, 210008, People’s Republic of China
, Zhenqing Feng5 Department of Pathology, Nanjing Medical University, Nanjing, Jiangsu, 211166, People’s Republic of China;6 Key Laboratory of Antibody Technique of Ministry of Health, Nanjing Medical University, Nanjing, Jiangsu, 211166, People’s Republic of ChinaCorrespondence[email protected]
& Baorui Liu1 The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, Jiangsu, 210008, People’s Republic of China;2 The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu, 210008, People’s Republic of ChinaCorrespondence[email protected]
show all
Pages 835-844
|
Published online: 05 Feb 2021
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.